Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 8, 2012, Pages 607-611

  Chambers, Christina D ^a   Johnson, Diana L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB;

ANENCEPHALUS; ANKYLOSING SPONDYLITIS; ATRIOVENTRICULAR SEPTAL DEFECT; AUTOIMMUNE DISEASE; BIRTH WEIGHT; CONCEPTION; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG HALF LIFE; DRUG THERAPY; DRUG USE; EVALUATION; FALLOT TETRALOGY; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOMA; HIP DYSPLASIA; HUMAN; IMMUNOCOMPROMISED PATIENT; INTESTINE MALROTATION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY AGENESIS; MATERNAL DISEASE; MEGACOLON; NEUROFIBROMATOSIS; NONHUMAN; PLACENTAL TRANSFER; POLYDACTYLY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYLORUS STENOSIS; REVIEW; RHEUMATOID ARTHRITIS; TRISOMY 18; TRISOMY 21; ULCERATIVE COLITIS; WOLFF PARKINSON WHITE SYNDROME;

ABNORMALITIES, DRUG-INDUCED; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; DATA COLLECTION; FEMALE; HALF-LIFE; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTERS; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865071492     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23033     Document Type: Review

References (31)

1. Andreoli L, Bazzani C, Taraborelli M, et al. 2010. Pregnancy in autoimmune rheumatic diseases: the important of counseling for old and new challenges. Autoimmun Rev 10: 51-54.
2. Bandoli G, Johnson DL, Jones KL, et al. 2010. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 163: 334-339.
3. Berthelot J-M, de Bandt M, Goupille P, et al. 2009. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76: 28-34.
4. Carter JD, Valeriano J, Vasey FB, et al. 2006. Tumor-necrosis factor-α inhibition and VATER association: a causal relationship? Case report. J Rheumatol 33: 1014-1017.
5. Carter JD, Ladhani A, Ricca L, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36: 635-641.
6. Chambers CD, Johnson DL, Robinson LK, et al. 2010. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 62: 1494-1503.
7. Cheent K, Nolan J, Shariq S, et al. 2010. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. J Crohn's Colitis 4: 603-605.
8. Gisbert JP 2010. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breastfeeding. Inflamm Bowel Dis 16:881-895.
9. Koren G, Inoue M. 2009. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 36: 465-466.
10. Hultzsch S, Weber-Schoendorfer C, Schaefer C. 2011. Pregnancy outcomes after exposure to etanercept. Abstract presented at ENTIS meeting, Jerusalem, Israel 31: 260.
11. Katz JA, Antoni C, Keenan GF, et al. 2004. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99: 2385-2392.
12. Kuriya B, Hernandez-Diaz S, Liu J, et al. 2011. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res 63: 721-728.
13. Lichtenstein GR, Feagan BG, Cohen RD, et al. 2006 Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 4:621-630.
14. Mahadevan U, Cucchiara S, Hyams JS, et al. 2011. 2011. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: pregnancy and pediatrics. Am J Gastroenterol 106: 214-223.
15. Mahadevan U, Kane S, Sandborn WJ, et al. 2005. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21: 733-738.
16. Murashima A, Watanabe N, Ozawa N, et al. 2009. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 68: 1792.
17. Murdaca G, Colombo BM, Cagnati P, et al. 2012. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 11: 1-5.
18. O'Donnell S, O'Morain C. 2008. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Alimen Pharmacol Ther 27: 885-894.
19. Ostensen M and Forger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. Cur Opin Rheumatol 23: 293-298.
20. Ostensen M, Brucato A, Carp H, et al. 2010. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatol 50: 657-664.
21. Pentšuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86: 328-344.
22. Roux CH, Brocq O, Breuil V, et al. 2007. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatol 46: 695-698.
23. Rump JA, Schonborn H. 2010. Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment. Z Rheumatol 69: 903-909.
24. Schnitzler F, Fidder H, Ferrante M, et al. 2007. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Gastroenterology 132: A144.
25. Schnitzler F, Fidder H, Ferrante M, et al. 2011. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 17: 1846-1854.
26. Toder V, Fein A, Carp H, et al. 2003. TNF-α in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Gen 20: 73-81.
27. Verstappen SMM, King Y, Watson KD, et al. 2011. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology biologics register. Ann Rheum Dis 70: 823-826.
28. Wakefield I, Stephens S, Foulkes R, et al. 2011. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFα PEGylated Fab' monoclonal antibody. Toxicol Sci 123: 170-176.
29. Wallenius M, Skomsvoll JF, Irgens LM, et al. 2011. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on firth birth. Arthritis Rheum 63: 1534-1542.
30. Weber-Schoendorfer C. 2011. Pregnancy outcomes in women exposed to adalimumab or infliximab; the experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy and Lactation. Abstract presented at ENTIS meeting, Jerusalem, Israel 31: 267.
31. Zelinkova Z, de Haar C, de Ridder L, et al. 2011. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 33: 1053-1058.